

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 66501

Title: The prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy

Reviewer's code: 05088021

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: United States

Author's Country/Territory: Japan

Manuscript submission date: 2021-03-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-23 13:15

Reviewer performed review: 2021-04-23 14:18

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Summary: This a well-written review paper on the prospect of lenvatinib for treatment of unresectable hepatocellular carcinoma (HCC). The paper adds to the growing literature on potential use of lenvatinib for systemic treatment for patients with advanced HCC. I don't not have any major concerns, except a few minor comments listed below: Minor comments: • Instead of using abbreviations like "Sor" and "Len" why don't you use the more recognizable names, "sorafenib" and "lenvatinib" for easy comprehension of the text? • In general, there are way too many abbreviations in the text, which should be reduced to about 4-5 abbreviations, unless they are well-known like "OS" for overall survival, or they are gene names. • Based on these results, Sor, Len, and Atezo+Bev could be administered to patients with unresectable HCC as first-line systemic chemotherapy." Authors should please make it clear that this is not a consensus agreement, but rather their opinion. • Page 10, last paragraph, "The proof of concept," should be "The proof-of-concept" • Page 11, referencing issue "{Kudo, 2020 #8}" and Page 12 "{Kawamura, 2020 #10}"

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 66501

Title: The prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy

Reviewer's code: 04213406

Position: Editorial Board

Academic degree: MD, MSc

Professional title: Assistant Professor, Lecturer

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Japan

Manuscript submission date: 2021-03-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-23 08:48

Reviewer performed review: 2021-04-30 09:10

Review time: 7 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

1- Please make the following statement in introduction section more easy to understand and digestible [Systemic chemotherapy is the only therapeutic option in patients with Child-Pugh grade A at Barcelona Clinic Liver Cancer (BCLC) stage C (advanced stage) and stage B (intermediate stage) in parallel with HCC unsuitable for locoregional therapy]. 2-Give more details [Therapeutic options for extrahepatic metastases and vascular invasion have been added] 3- I recommend rewrite the introduction section provided that it should reflect the problem of unrespectable HCC and available therapeutic options from past to present in simple and smooth methods. 4- 7 what mm or cm or inches or criteria[a large tumor mass such as beyond up-to-7]?! 5- Is the following statement true?[two or more consecutive progressions in the liver (tumor number increases before the previous TACE procedure] 6-{Kawamura, 2020 #10} page 12 ? please edit it